drugset / Trial / NCT00366262

Study Evaluating the Gastrointestinal Safety of PLA-695 Compared to Placebo and Naproxen

NCT00366262

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to provide an initial assessment of the gastrointestinal safety of a 7-day regimen of PLA-695 compared to placebo or naproxen.

Timeline

Start
2006-06
Primary completion
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject GIRIPLADIB Small molecule
Subject Naproxen Small molecule

Indications

No indication recorded.